To include your compound in the COVID-19 Resource Center, submit it here.

Countdown on Avastin

With the biotech sector desperate for positive product news, attention will be turning to Avastin from Genentech Inc., which is aiming to disclose its first Phase III data by the end of the quarter, in breast cancer.

Thus

Read the full 377 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE